代谢和微生物见解:Kai-Xin-San对阿尔茨海默病病理学的影响
Huifen Ma1,2, Zhiyang Yu2, Qiong Qiao2
1Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China.
iScience
|July 2, 2025
概括
凯辛桑 (KXS) 通过改变肠道细菌和代谢物,可以预防阿尔茨海默病 (AD). 这项研究表明,KXS影响肠道微生物群和代谢物,可能减少AD模型中的神经炎症.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 与肠道微生物群和代谢物变化有关.
- 开新圣 (KXS) 是一种用于治疗痴呆症的中国传统医药.
- 对于KXS在阿尔茨海默病中的保护作用的机制,特别是其与肠道微生物群的联系,尚不清楚.
研究的目的:
- 在阿尔茨海默氏病 (AD) 鼠标模型中研究Kai-Xin-San (KXS) 对肠道微生物群和代谢物的影响.
- 探索KXS,肠道微生物群,代谢物和AD中神经炎症之间的关系.
主要方法:
- 使用APP/PS1小鼠作为AD模型.
- 采用非向的代谢学来识别43个受到KXS影响的关键代谢物.
- 使用16S rRNA测序来分析肠道微生物群的组成.
主要成果:
- KXS显著改变了特定的肠道细菌属,包括Clostridium_IV,Eubacterium和Acetatifactor.
- 确定了9种与13种与认知障碍相关的差异代谢物相关的肠道菌群属.
- 治疗KXS抑制神经炎症,主要是通过调节关键代谢物.
结论:
- KXS证明了对AD的潜在保护作用.
- 该机制涉及调节肠道微生物群和代谢物概况.
- 这些发现表明,肠道微生物群,代谢物和神经炎症之间的联系在KXS对AD的治疗作用中.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
988
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
674
相关概念视频
01:26Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265